Chemical approaches to sphingolipid research by Delgado Cirilo, Antonio et al.
 Research Signpost 
 37/661 (2), Fort P.O. 
 Trivandrum-695 023  
 Kerala, India 
 
 
 
 
Recent Advances in Pharmaceutical Sciences V, 2015: 1-12 ISBN: 978-81-308-0561-0                                                                                                                                               
Editors: Diego Muñoz-Torrero, M. Pilar Vinardell and Javier Palazón 
 
1. Chemical approaches to sphingolipid 
research 
 
Antonio Delgado1, Josefina Casas2, José Luis Abad2  
and Gemma Fabriàs2 
1University of Barcelona (UB); Faculty of Pharmacy; Department of Pharmacology and Medicinal 
Chemistry; Unit of Pharmaceutical Chemistry (Associated Unit to CSIC); Avga. Joan XXIII s/n,                         
E-08028 Barcelona, Spain; 2Research Unit on BioActive Molecules; Department of Biomedicinal 
Chemistry; Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26;                        
E-08034 Barcelona, Spain 
 
Abstract. Sphingolipids are an important group of biomolecules 
that play important roles in the regulation of many cell functions. 
Many efforts have been made in recent years to design analogs 
suitable for a better understanding of the biological and biophysical 
roles of sphingolipids. In this review, some of the most relevant 
contributions in the field from our group are collected. In particular, 
this review deals with the development of new sphingolipid analogs 
as acid ceramidase inhibitors, and the design of fluorogenic probes 
to screen enzyme activities and to the study of biophysical 
properties. 
 
Introduction 
 
 Sphingolipids (SLs) represent an important group of natural products 
that play crucial roles in cell survival and regulation [1]. Chemically, SLs in  
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mammals contain a lipophilic 2-amino-1,3-diol backbone of eighteen 
carbon atoms, as found in sphingosine (So). Acylation of the 2-amino 
group with fatty acids affords ceramides (Cer), responsible for grow 
inhibition and apoptotis. The so-called complex SLs arise from 
functionalization at the primary hydroxyl group of Cer. In this case, 
glucosylation leads to glucosyl ceramide (GlcCer), the precursor of higher 
glycosphingolipids (GSLs), which play important roles in cell-cell 
recognition events at the outer membrane [2]. Esterification with 
phosphorylcholine leads to sphingomyelin (SM), while both Cer and Sph 
can be also phosphorylated in cells to the corresponding phosphate esters, 
ceramide-1-phosphate (CerP) [3] and sphingosine-1-phosphate (S1P) [4], 
which are important as second messengers and also in cell regulation as 
proliferative agents (Fig. 1).  
 
 
 
Figure 1. Some of the most representative sphingolipids in mammals. 
 
 The effective control of the cellular functions requires a delicate balance 
of SL levels, which is regulated by finely tuned complex metabolic pathways 
with the help of specific enzymes However, the enzymatic processes by 
themselves are not enough to understand this intricate scenario, whose 
operability depends on the cellular compartmentalization of the different 
pathways involved (Fig. 2) [1]. This cellular organization is especially 
relevant for signaling events mediated by SL that are often spatially 
separated in particular organelle. Since the subcellular distribution of lipids 
is not uniform [5], local changes in lipid concentrations can be responsible 
for diverse downstream effects. 
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Figure 2. Metabolic pathways and compartmentalization in sphingolipid 
biosynthesis. (CERT: ceramide transporter protein; dhCer: dihydroceramide; dhKSo: 
ketosphingosine; dhSo: dihydrosphingosine; GSL: glycosphingolipids; NCDase: 
neutral ceramidase; NSmase: neutral sphingomyelinase; SK: sphingosine kinase; 
FAPP2: GlcCer transfer protein). 
 
 The fact that the expression of SL metabolizing enzymes is deregulated 
in many diseases has boosted the design of SL biosynthesis modulators as a 
rational approach to define new targets and new small molecule chemical 
entities with potential therapeutic applications [6].  
 In recent years, the interest on the biophysical properties of SLs, in 
particular So, Cer and their phosphorylated derivatives, has emerged as a 
major field of research. In this context, So is known to increase membrane 
permeability, while Cer increase lipid chain order, induce “flip-flop” motion 
of lipids and segregate laterally into rigid domains, among other effects [7]. 
Interestingly, it is the ability of these SL to aggregate into microdomains 
what accounts for the formation of high local concentrations of secondary 
messengers that are ultimately responsible for the triggering of some cellular 
effects. 
 
1. Sphingolipid analogs as enzyme inhibitors 
 
 Abnormal SLs metabolism is known to occur in some diseases, such as 
certain sphingolipidoses [6], cancer [8], diabetes [9], and aterosclerosis [10]. 
The cellular contents of the various SLs species are controlled by enzymes 
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involved in their metabolic pathways. In this context, the search for potent 
and selective inhibitors of SL metabolizing enzymes offers new insights for 
the discovery of alternative therapeutic agents. Our interest in SL enzymes 
as potential targets led us to investigate on ceramidases, a type of 
amidohydrolases that catalyze the cleavage of Cer into So and fatty acids. 
According to their optimal pH, ceramidases fall into three groups, acidic 
(aCDase), neutral (NCDase) and alkaline ceramidases (alkCDase). While 
aCDase is ubiquitously expressed, NCDase is highly expressed in the small 
intestine along the brush border, where it is involved in the catabolism of 
dietary sphingolipids thus regulating the levels of bioactive sphingolipid 
metabolites in the intestinal tract. On the other side, alkaline ceramidases are 
expressed in the endoplasmic reticulum, where three different types have 
been identified, based on their localization and the encoding genes [11].  
 The role of CDases in human disease is well documented. In general, 
increased CDase activity leads to reduced levels of ceramides and increased 
amounts of S1P, which results in increased resistance to cytotoxic signals. 
This situation is often found in cancer progression and resistance to 
treatments. On the other hand, a decrease of ceramidase activity provokes 
cell death. A number of reports point to important roles of ceramidases, 
mainly aCDase, in the initiation and progression of cancer, and the response 
of tumours to therapy [12]. Overexpression of aCDase is found in several 
cancer cell lines and cancer tissues [13], which appears to contribute to 
decreasing the levels of Cer and increasing those of S1P, thereby resulting in 
resistance to cell death and enhancement of cell proliferation. In most cases, 
aCDase inhibition induces apoptosis. Multiple reports confirm the 
relationship between aCDase activity and radio- or chemotherapy resistance, 
as well as the interest of aCDase inhibitors as anticancer drugs, either alone 
or in combination with other therapies [11]. The research in this field has led 
to implicate an over-expression of acid ceramidase (aCDase) in metastatic 
prostate cancer [14]. Many tumor types express high levels of acid 
ceramidase (aCDase). Specifically, the expression levels of aCDase in 
prostate cancer have been reported to be elevated relative to normal prostate 
tissue [15]. With these considerations in mind, a rational design of an 
aCDase inhibitor was undertaken. Taking into account that aCDase is a 
cysteine hydrolase, a small family of Cer analogs modified at the amide 
linkage with thiol reactive functions was generated and tested. These 
compounds were inspired in reported cysteine protease inhibitors [16] and 
included two β-haloamides and several α,β–unsaturated amides as Michael 
acceptors, as shown in Fig. 3. 
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Figure 3. New acid ceramidase inhibitors. 
 
 The best inhibitors in intact cells were compounds RBM1-12, RBM1-13, 
RBM1-18 and SABRAC, with percentages of inhibition ranging from 50 to 
70%. Compounds RBM1-12, RBM1-13, and SABRAC were selected for 
further studies and were shown to be selective aCDase inhibitors in light of 
their lack of activity on NCDase, the enzyme that hydrolyses Cer in the cell 
membrane. In vitro dose-response determinations showed that SABRAC 
was the best inhibitor, with an IC50 value of 52 nM, followed by RBM1-12 
(IC50 = 0.53 µM) and RBM1-13, which exhibited the lowest potency (IC50 = 
11.2 µM). Furthermore, in the presence of SABRAC and RBM1-12, the 
enzyme activity showed an exponential decay versus incubation time at two 
protein concentrations, this indicating an irreversible type of inhibition. The 
above observations confirmed aCDase as a therapeutic target in advanced 
and chemoresistant forms of prostate cancer and suggested that our new 
potent and specific inhibitors could act by counteracting critical growth 
properties of these highly aggressive tumor cells. 
 
2. Sphingolipid analogs as fluorogenic probes 
 
 The perception that SL metabolism is composed of a highly intricate, 
interrelated system of enzymes, whose relative activities determine the 
intracellular concentration of SLs and, ultimately, the cell fate, has boosted 
the development of methods to monitor SL enzyme activity. In this context, 
the use of fluorogenic substrates (substrates that give rise to a fluorescent 
readout subsequent to a particular enzymatic reaction) represents a 
breakthrough in the design of probes suitable for determining enzyme 
activities. Guided by these interests, our group has been working actively in 
the development of new fluorogenic probes for the development of HTS 
methods for the screening of several SL metabolizing enzymes. With our 
focus on aCDase, the fluorogenic coumarinic substrates RBM14 (Fig. 4) 
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were designed. After the enzymatic hydrolytic amide cleavage of the above 
substrates, oxidation of the resulting vicinal amino diol renders an 
intermediate aldehyde AL (Fig. 4), whose subsequent β-elimination under 
basic conditions liberates the fluorescent reporter (Fig. 4) [17,18]. 
Interestingly, the specificity of the substrates towards ceramidases could be 
modulated by choosing an appropriate acyl chain length. Thus, for aCDase, 
the highest rate of hydrolysis was observed for the probe with a dodecanoyl 
group (RBM14-12). The recombinant human neutral ceramidase preferred 
the hexadecanoyl derivative (RBM14-16), while the tetradecanoylamide 
(RBM14-14) was preferentially hydrolyzed by lysates of neutral 
ceramidase-null mouse embryonic fibroblasts at pH 8.5 in the presence of 
Ca
+2
. It is worth mentioning that this fluorogenic method is currently used 
for the diagnosis of Farber disease, a rare disease characterized by the 
deficiency of aCDase [18]. 
 The in situ generation of umbelliferone as a fluorescent reporter to 
monitor SL enzyme activity was also been applied for the development of a 
HTS protocol for sphingosine-1-phosphate lyase (SPL). This enzyme plays 
an important role in cellular functions linked to tumor progression and 
immunosuppression [19]. It catalyzes the retroaldol cleavage of long chain 
base phosphates into phosphoethanolamine and a fatty aldehyde (Fig. 5). 
Since both saturated and unsaturated, as well as truncated base phosphates 
are transformed by SPL and the reaction is highly stereoselective for the 
d-erythro isomer [20], we reasoned that compound RBM13 contained the 
required structural features to behave as a suitable SPL substrate. 
 
 
 
Figure 4. Fluorogenic coumarinic fluorogenic probes to determine CDase and SPL 
activities. 
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Figure 5. Retroaldol reaction catalyzed by SPL. 
 
 Upon enzymatic cleavage, aldehyde AL (Fig. 4) is first produced to 
render the fluorescent umbelliferone reporter after β-elimination under 
alkaline conditions [21]. In our optimized protocol, the assay can be 
performed in microtiter wells, and can be easily adapted to HTS formats. 
 The above substrates were inspired in the pioneering works by Reymond 
and co-workers for the development of a fluorogenic assay for hydrolytic 
enzymes [22]. 
 The synthesis of the above probes can be carried out starting from 
Garner’s aldehyde, following the approach indicated in Fig. 6. The common 
intermediate B, obtained from acidic hydrolysis of A, arising, in turn, from 
Garner’s aldehyde in five synthetic steps [17], was selectively 
phosphorylated at the primary hydroxyl group, to give C, and further 
deprotected in a one-pot two-step process to the required amino phosphate 
RBM13. Alternatively, Boc removal from intermediate B, followed by 
standard N-acylation afforded the required RBM14 probes. 
 
 
 
Figure 6. Synthesis of the fluorogenic coumarinic probes RBM13 and RBM14. 
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3. Azidosphingolipids as probes to study membrane 
organization 
 
 The use of synthetic lipid probes for biophysical applications is a 
well-recognized strategy in lipid research [23]. In particular, the use of 
fluorescent tags is useful for the visualization of the membrane architecture 
and the study of its dynamic properties. The suitability of the substrate is 
determined by its ability to afford a fast and sensitive detection and also to 
behave similarly as its untagged counterpart. These two requirements are 
somehow contradictory when large aromatic fluorescent moieties are used. 
Because natural membrane lipids do not have such bulky fluorescent tags, 
dramatic effects on the properties of the resulting probes can be expected, 
especially as far as trafficking, sorting and/or domain formation is concerned 
[24]. Ideally, a suitable probe should be structurally similar to its natural 
counterpart and allow an efficient in situ chemoselective functionalization 
with a suitable fluorescent reagent in a natural environment. These 
requirements can be envisaged by a judicious use of bioorthogonal chemical 
reporter strategies, a technique that has become common place for the 
labelling of biomolecules [25,26]. Based on these premises, and aiming to 
widen the scope of our research, we undertook the synthesis of the α- and 
ω-azido probes RBM2-79 and RBM 2-77 shown in Fig. 7. As sphingolipid 
analogs, these probes are amenable to incorporation into natural or artificial 
membranes. In addition, due to the presence of the terminal azido group, the 
possibility of a bioorthogonal alkyne-azide cycloaddition “click” reaction 
with the fluorogenic tag D [27] was considered. 
 
 
 
Figure 7. Design of bioorthogonal “click” reactions with azido sphingolipid probes 
RBM2-77 and RBM2-79. Doble enlace en triazol 
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 In this context, the recent advances in the development of bioorthogonal 
reactions have boosted their applications in chemical biology [28]. In 
particular, those involving the Cu(I)-catalyzed Huisgen [3+2] cycloadditions 
of terminal alkynes with azides [29] (CuAAC, the paradigm of “click 
chemistry” [30]) have become attractive to researchers due to their 
simplicity and high reactivity. In order to avoid the potential toxicity of 
Cu(I) salts, several modifications have been developed to reduce Cu(I) 
concentration, as the use of water-soluble Cu(I) ligands [31,32] or 
Cu(I)-chelating azides [33]. 
 In our case, the probes shown in Fig. 7 have been designed to mimic the 
behaviour of natural ceramides in artificial membranes [34]. Membrane 
ceramides are important metabolic signals [35,36] that are known to separate 
laterally to give rise to gel-like ceramide-enriched domains [37–39]. Because 
of their structural similarity, our probes RBM2-77 and RBM2-79 were able 
to orient in lipid bilayers in parallel with the phospholipids, and eventually to 
give rise to domains similarly to natural ceramides. Gratifyingly, our in situ 
synthetic method allowed the observation of ceramide domains in living 
cells.  
 Click reactions required the use of an in situ generated Cu
+
 catalyst by 
ascorbate promoted reduction of a Cu
2+
 salt. The photoactivation of the 
probes was checked by microscopy experiments using giant unilamellar 
vesicles (GUVs) of ePC:1 and ePC:2 (10 mol% of clickable probe in both 
cases). When GUVs were treated with the labeling solution, a clear 
fluorescence intensity was collected in both cases between 450-500 nm, 
which was attributed to the formation of the corresponding fluorescent click 
cycloadducts shown in Fig. 7. This fluorescence was not observed when 
GUVs were incubated under control conditions (in the absence of the Cu
2+
 
salt catalyst precursor) after 3h incubation. These results constitute a proof 
of principle that fluorescent ceramide derivatives may be formed within lipid 
membranes starting from minimally modified non-fluorescent azido 
sphingolipids. This technique can be extended to the study of 
ceramide-enriched domains by fluorescent confocal microscopy and also to 
the study of the so-called ceramide platforms [40]. Finally, despite Cu
2+
 may 
be toxic to cells, localization of ceramide-rich domains in cell membranes 
can be performed on fixed cell preparations. In any, case, the use of Cu-free 
click chemistry protocols [41] is also considered as a natural evolution of 
this technique.  
 The above probes were synthesized following standard protocols, as 
exemplified for RBM2-77 in Fig. 8. Thus, the cross methathesis [42,43] of 
11-bromo-1-undecene with vinyl alcohol E, obtained from Garner’s 
aldehyde following a reported protocol [44], afforded bromide F in moderate  
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Figure 8. Synthesis of probe RBM2-77; a: 11-bromo-1-undecene, Grubb’s 2nd 
generation, CH2Cl2, 45 ºC, 59%; b: NaN3, DMF, 80 ºC (93%); c: ClCOCH3, MeOH, 
rt, 1h (84%); d: C15H31COOH, EDC. HOBt, Et3N, CH2Cl2, 65%. 
 
yield and excellent E-selectivity. Reaction of F with excess NaN3 in DMF at 
80 ºC, followed by the simultaneous deprotection of the oxazolidine and 
N-Boc groups of intermediate azide G under acidic conditions, afforded 
RBM2-31 in excellent yield. Acylation with palmitic acid, using EDC/HOBt 
as coupling system, afforded probe RBM2-77. 
 
4. Conclusions 
 
 In this review we have tried to show the potential of the chemical 
modifications of sphingolipids by means of a selection of some of our recent 
results in this area. Thus, the biochemical functions of natural sphingolipids 
can be efficiently modulated by the judicious design of analogs addressed at 
interfering with specific enzymes of key sphingolipid metabolic pathways. 
In this account, this approach has been illustrated with the design of a new 
family of aCDase inhibitors, which have also allowed the identification of 
this enzyme as a therapeutic target in chemoresistant forms of prostate 
cancer. In a conceptually different approach, chemical modifications of 
sphingolipids have also been used to design chemical probes with specific 
applications in structural and cell biology. This is the case of the fluorogenic 
probes RBM13 and RBM14, designed to develop HTS protocols to monitor 
the activity profiles of SPL and CDases, respectively. In a related context, 
the azido sphingolipids RBM2-77 and RBM2-79 have found applications in 
structural biology for their ability to visualize the membrane organization of 
natural ceramides after a biorthogonal click reaction with a suitable 
fluorogenic reporter. 
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